40 results about "Heterologous Antibodies" patented technology

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.

The present invention provides a non-human animal-derived antiserum and/or non-human animal-derived immunoglobulin against the 2019-nCOV (SARS-CoV-2). The invention is intended to be able to be used in the treatment and prevention of novel coronavirus pneumonia.

A serum in which are dissolved at least two heterologous antibodies, which are independently IgG or IgM and which specifically bind to different antigens, serves as a calibrator for multi-analyte immunoassays.

The invention discloses a humanized single-chain antibody 8B of clostridium perfringens alpha-toxin. The humanized single-chain antibody 8B is screened from a phage antibody library Source bioscience, is a full-humanized antibody of the clostridium perfringens alpha-toxin and can be used for achieving a toxin neutralization treating effect, overcoming various side effects of a heterologous antibody and eliminating complex steps and high cost of humanization modification on the heterologous antibody; and the single-chain antibody is small in molecular weight, strong in in-vivo penetrability and capable of rapidly reaching to damaged tissues and cells to exert an antitoxin effect, so that the double aims of economy and high efficiency are achieved. The alpha-toxin has a certain homology with other types of toxins of clostridium perfringens, so that the antibody drug possibly generates inhibiting and treating effects for other types of toxins and can also be used as a detecting reagent to detect the clostridium perfringens alpha-toxin.

A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and alight chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF encode a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5′ and 3′ ITRs flank the expression cassettes and regulatory sequences.

The invention discloses a humanized single-chain antibody 7D of clostridium perfringens alpha-toxin. The humanized single-chain antibody 7D is screened from a phage antibody library Source bioscience, is a full-humanized antibody of the clostridium perfringens alpha-toxin and can be used for achieving a toxin neutralization treating effect, overcoming various side effects of a heterologous antibody and eliminating complex steps and high cost of humanization modification on the heterologous antibody; and the single-chain antibody is small in molecular weight, strong in in-vivo penetrability and capable of rapidly reaching to damaged tissues and cells to exert an antitoxin effect, so that the double aims of economy and high efficiency are achieved. The alpha-toxin has a certain homology with other types of toxins of clostridium perfringens, so that the antibody drug possibly generates inhibiting and treating effects for other types of toxins and can also be used as a detecting reagent to detect the clostridium perfringens alpha-toxin.

The invention relates to a humanized anti-PSMA single-chain antibody, which includes a heavy chain and a light chain which are connected with a linker. The nucleotide sequence of the heavy chain is coded as SEQ ID NO.1, and the nucleotide sequence of the light chain is coded as SEQ ID NO.2. An effective antibody preparation is provided for diagnosis, treatment and prognosis of prostate cancer. Compared with a PSMA murine monoclonal antibody in the prior art, the humanized anti-PSMA single-chain antibody has a different source, and the toxic and side effects of a heterologous antibody on a human body is avoided.

The present invention provides systems, kits, and methods for analyzing cell-cell interactions, such as transmembrane proteins binding to surface displayed variable regions, via discrete entity (e.g., droplet) microfluidics. In certain embodiments, a plurality of first discrete entities and a plurality of second discrete entities are merged on a substrate to generate a plurality of merged fixed entities (e.g., fixed via an electrical force), each of which contains one cell expressing a transmembrane (TM) protein and labeled clonal cells displaying a heterologous antibody variable region. In certain embodiments, any binding of the clonal cells to the TM expressing cell is detected in each merged fixed entity, and the clonal cells found to bind are treated in order to sequence the nucleic acid encoding the variable region.

The invention discloses a tilapia growth hormone quantitative determination kit based on timed-resolved fluoroimmunoassay and heterologous antibody. The kit comprises a micropore reaction plate coated with a saddletail grouper growth hormone specific single chain monoclonal antibody, a recombination tilapia growth hormone protein standard substrate, and an europium-labelled saddletail grouper growth hormone hormone specific single chain monoclonal antibody. Through immunization reaction with a antibody sandwich method, the recombination tilapia growth hormone protein standard substrate or a to-be-detected sample is added in the micropore reaction plate coated with the saddletail grouper growth hormone specific single chain monoclonal antibody, incubation combination is carried out, then board-washing is carried out, then the europium-labelled saddletail grouper growth hormone hormone specific single chain monoclonal antibody is added, incubation combination is carried out, then board-washing is carried out, enhancement liquid is added, and determination is carried out through a multifunctional ELIASA. The kit can be used for detecting growth hormone concentration of growth hormone-containing samples such as tilapia serum or a pituitary lysate, the detection sensitivity can reach 0.225 ng/ml, and the kit provides effective detection means for researching the tilapia growth hormone.

A Class III, anti-CEA monoclonal antibody, preferably a monoclonal antibody comprising the complementarity-determining regions (CDRs) of a parental murine Class III, anti-CEA monoclonal antibody is disclosed. This monoclonal antibody is preferably a humanized monoclonal antibody in which the CDRs are engrafted to the framework regions of a heterologous antibody, wherein the humanized monoclonal antibody retains the binding specificity of the parental murine monoclonal antibody. A preferred Class III, anti-CEA monoclonal antibody is one in which the preferred heterologous antibody is from a human. Also provided are DNA constructs, vectors, cells and methods for producing the Class III, anti-CEA monoclonal antibodies, and diagnostic and therapeutic conjugates using same. Methods of treatment with a Class III, anti-CEA monoclonal antibody and with the conjugate containing this monoclonal antibody are provided as well as methods of diagnosis with the conjugate containing this monoclonal antibody.

The invention belongs to the field of antibody engineering, and provides a method for obtaining a high-purity heterologous antibody. The heterologous antibody contains two heavy chains with different amino acid sequences, wherein a mutation is introduced into the I253 of the constant region of one heavy chain, and through protein A affinity chromatography purification, a high-purity bispecific antibody can be obtained, wherein the position of the above amino acid is determined according to an EU index numbered by KABAT. By use of the method disclosed by the invention, one mutation is introduced into the heavy chain, Ile of which the EU number is on the 253rd site in the constant region of the heavy chain is mutated into Asn, i.e., the purity of the heterologous antibody can be improved to be 99% or above only through one-step protein A affinity chromatography, purification steps are greatly simplified, preparation cost is lowered, and the method has a wide commercial application prospect.

The present invention relates to: a method for producing an egg yolk antibody for preventing or treating calf digestive diseases, which comprises producing a heterologous antibody by using a calf digestive disease-causing bacterium or a viral antigen, and then inoculating a laying chicken with a complex that binds the antigen and the heterologous antibody, thereby producing the yolk antibody; theegg yolk antibody produced thereby and the use thereof. According to the invention, the method for producing an egg yolk antibody for preventing or treating calf digestive system diseases realizes mass production and production of an egg yolk antibody by injecting an antigen-heterologous antibody complex into an egg laying chicken, the egg yolk antibody produced thereby has high specificity and binding properties with respect to calf digestive system disease pathogenic bacteria or virus, and can effectively inhibit the growth of the bacteria and virus, thereby preventing or treatment calf digestive system diseases.

The present invention relates to a method for preparing an anti-Helicobacter pylori egg yolk antibody, comprising injecting a Helicobacter pylori antigen into an animal that is different from a chicken so as to prepare a heterologous antibody, and then injecting, into a laying hen, a complex in which the antigen and heterologous antibody are combined, thereby preparing an egg yolk antibody. According to the present invention, the method for preparing an anti-Helicobacter pylori egg yolk antibody, of the present invention, can mass-manufacture and -produce an egg yolk antibody through the injection of a heterologous antigen-antibody complex into a laying hen, and the egg yolk antibody prepared thereby has high specificity and avidity to Helicobacter pylori, thereby effectively inhibiting the bacteria.